Clinicians have documented a rare occurrence of subcutaneous panniculitis-like T cell lymphoma in a 41-year-old female patient undergoing disease-modifying therapy for relapsing-remitting multiple sclerosis. The report, published as a letter to the editors in the Journal of Neurology, describes the diagnostic pathway, treatment adjustments, and clinical course following the onset of cutaneous lesions during and after anti-CD20 monoclonal antibody treatment.
The patient was initially diagnosed with relapsing-remitting multiple sclerosis in January 2020 at the age of 35 and had not received any prior disease-modifying treatments. Initial therapy consisted of ocrelizumab, a humanised monoclonal antibody engineered to selectively target CD20-positive B cells. Following initiation of ocrelizumab, the patient experienced a rapid and marked reduction in serum immunoglobulin M concentrations.
Cutaneous symptoms began to manifest in August 2023 with an erythematous lesion located in the inframammary fold, which clinical evaluators initially interpreted as hidradenitis suppurativa. In October 2024, a soft-tissue lesion developed on the patient’s right shoulder. In light of these recurring dermatological manifestations and persistent low serum immunoglobulin M levels, clinicians discontinued ocrelizumab therapy in May 2024 due to safety concerns.
Between December 2024 and January 2025, clinicians evaluated an inflamed suprascapular soft-tissue lesion that was initially diagnosed as an inflamed sebaceous cyst with lymphocytic infiltrate.
In May 2025, clinicians initiated maintenance therapy with natalizumab after serological screening confirmed low-intermediate anti-JC virus antibody indices, comprising a STRATIFY index of 0.70 and an ImmunoWELL index of 1.08. However, a repeat biopsy of the persistent right suprascapular lesion performed in July 2025 demonstrated histological features characteristic of both lymphocytic panniculitis and a panniculitis-like T cell lymphoproliferative process. Molecular diagnostic testing confirmed monoclonal rearrangement of T cell receptor gamma genes, while Epstein-Barr virus testing was negative, leading to the immediate withdrawal of natalizumab.
By August 2025, additional cutaneous lesions had emerged across the patient’s face, trunk, and lower extremities. A formal histological evaluation completed in September 2025 confirmed a diagnosis of peripheral T cell lymphoma displaying specific features of subcutaneous panniculitis-like T cell lymphoma, a rare subtype of primary cutaneous lymphoma.
Systemic staging using whole-body fluorodeoxyglucose positron emission tomography combined with computed tomography in October 2025 demonstrated multiple foci of elevated glucose metabolism throughout the subcutaneous tissues. Concurrent whole-body computed tomography identified solid subcutaneous tissue formations at the left cheek, the right scapular region, and the left paramedian cervical and dorsal regions, with thin strands of pathological tissue extending along the spine, in the absence of detectable lymphadenopathy.
The patient began systemic chemotherapy in November 2025, receiving an intensive CHOEP protocol consisting of cyclophosphamide, hydroxydaunorubicin, vincristine, etoposide, and prednisone. Chemotherapy concluded in March 2026, and follow-up magnetic resonance imaging of the brain and spinal cord conducted in May 2026 showed no radiological evidence of multiple sclerosis disease activity, with the patient experiencing no clinical neurological relapses following the cessation of disease-modifying therapy.
The authors contextualised the findings by comparing them to a previously published case by Teofilo and colleagues, in which a 42-year-old female with multiple sclerosis developed mycosis fungoides after receiving the anti-CD20 antibody ofatumumab before switching to natalizumab. Notable clinical contrasts exist between the two presentations: the earlier patient had received several disease-modifying agents prior to anti-CD20 therapy, whereas the present patient was treatment-naïve, and the duration of ofatumumab exposure was roughly half that of the ocrelizumab regimen. Furthermore, mycosis fungoides represents an epidermotropic CD4-positive malignancy favouring sun-shielded skin, whereas subcutaneous panniculitis-like T cell lymphoma primarily produces deep-seated plaques and subcutaneous nodules across the trunk and extremities.
The authors noted that sequential immune modulation from ocrelizumab involves immediate suppression of B cell pathways followed by gradual downregulation of T cell-mediated immunity. While B cell depletion can perturb T cell regulation and tolerance, the authors stressed that causality cannot be inferred from isolated reports. Because cutaneous T cell lymphomas have also been documented during other disease-modifying therapies such as fingolimod, and existing epidemiological evidence does not demonstrate an elevated lymphoma risk with anti-CD20 agents, the authors concluded that a coincidental occurrence remains likely while underscoring the role of vigilant clinical monitoring.
The authors emphasized the distinct pharmacological rationale that guided the selection of natalizumab following the cessation of ocrelizumab. Clinicians chose natalizumab because of its well-established clinical safety profile and its fundamentally different mechanism of action compared to anti-CD20 agents. Rather than depleting circulating B cell pools, natalizumab acts by selectively inhibiting lymphocyte trafficking, an approach that in theory preserves peripheral immune surveillance. The authors noted that adopting natalizumab as a sequential treatment strategy for people receiving anti-CD20 therapy may be an appropriate therapeutic pathway, particularly in clinical scenarios where patients present with an increased incidence of infection or other emerging safety concerns.
Because both mycosis fungoides and subcutaneous panniculitis-like T cell lymphoma represent exceptionally rare subtypes of primary cutaneous T cell lymphoma, the authors speculated that a biological relationship might link anti-CD20 therapy to the occurrence of lymphoproliferative disorders in multiple sclerosis. Although establishing definitive causality is not possible from isolated clinical observations, prolonged therapeutic depletion of B cells could plausibly perturb broader immune regulation and disrupt normal T cell homeostasis.
In particular, regulatory B cell populations are essential for maintaining peripheral immune tolerance by suppressing pathogenic T cell responses and supporting the ongoing functional activity of regulatory T cells.
To contextualize their observations, the authors drew comparisons to other therapeutic contexts involving profound B cell clearance, noting that rare T cell lymphoproliferative disorders have also been reported following B cell depletion induced by CD19-directed chimeric antigen receptor T cell therapies. Although the absolute risk of developing such secondary T cell conditions after CD19-directed therapies appears very low and causality remains unproven, the appearance of lymphoproliferative events across different B cell-depleting strategies warrants continued scientific consideration. Current clinical and molecular data suggest that any potential association between therapeutic B cell depletion and subsequent lymphoproliferative disorders is likely multifactorial in origin. Such processes may involve an intricate combination of underlying immune dysfunction, viral reactivation, preexisting clonal hematopoiesis, and, in rare instances associated with cellular therapies, vector-related genetic events.
At the same time, the authors stressed that the emergence of cutaneous T cell lymphomas during multiple sclerosis therapy cannot be considered a phenomenon unique or specific to anti-CD20 targeted monoclonal antibodies. Medical literature has previously documented instances of mycosis fungoides developing in multiple sclerosis patients during treatment with fingolimod.
From an epidemiological perspective, the authors affirmed that the onset of rare lymphoproliferative disorders in multiple sclerosis patients treated with anti-CD20 monoclonal antibodies cannot be considered a drug-related effect by itself. Nonetheless, they maintained that reporting and tracking these rare occurrences remains vital for clinical practice, highlighting the ongoing importance of careful patient monitoring to properly balance therapeutic benefits against potential adverse events over long-term treatment courses.
Subject of Research: Case report of subcutaneous panniculitis-like T cell lymphoma during multiple sclerosis therapy
Article Title: Subcutaneous panniculitis-like T cell lymphoma in a patient with multiple sclerosis during anti-CD20 therapy: a case report
Article References: Amati, F., Chiapparino, C., Franco, G., Frisone, G., & Ardito, B. (2026). Subcutaneous panniculitis-like T cell lymphoma in a patient with multiple sclerosis during anti-CD20 therapy: a case report. Journal of Neurology, 273(11), Article 694. https://doi.org/10.1007/s00415-026-14233-x
Image Credits: AI Generated
DOI: 10.1007/s00415-026-14233-x
Keywords: Multiple Sclerosis, Ocrelizumab, Anti-CD20 Therapy, Subcutaneous Panniculitis-Like T Cell Lymphoma, Natalizumab, Neurology, Case Report, Lymphoproliferative Disorders, Subcutaneous, panniculitis-like, cell, lymphoma
News Source: Ophelia Keating. (November 7, 2026). Case Report Examines Rare T-Cell Lymphoma During Multiple Sclerosis Treatment. Scienmag.



